Hogan Lovells logo
  • Our people
  • What we do
    Sectors Practices Legal Tech
    • Aerospace and Defense
    • Automotive and Mobility
    • Consumer
    • Education
    • Energy
    • Financial Institutions
    • Insurance
    • Life Sciences and Health Care
    • Manufacturing and Industrials
    • Private Capital
    • Real Estate
    • Sports, Media and Entertainment
    • Technology
    • Transportation and Logistics
    • Corporate & Finance
    • Disputes
    • Intellectual Property
    • Regulatory
  • Case studies
  • Our thinking
    • All Our thinking
    • Comparative guides
    • Digital Client Solutions
    • Events and webinars
    • Podcasts
    News image_2

    Reflecting on President Trump’s first 100 days in office

  • ESG
  • Careers
Search Search
close
Search Search Search
lang-sel-icon English
  • Deutsch
  • English
  • Español
  • Français
  • 日本語
  • 中文
False
people-new
Mobile area
  • About us
    • Overview
    • Our history
    • Global management team
  • Where we are
    • Our locations
    • Law Firm Network
  • Media center
    • Media contacts
    • Press releases
    • Awards & rankings
  • Responsible Business
  • HL Inclusion
  • Alumni
LinkedIn
Youtube
twitter
Wechat
News

340B Program: HRSA Proposes to Modify Administrative Dispute Resolution Process

06 December 2022
Image
Image
wechat x linkedin
hogan-lovells-logo
Share by email
Enter email
Enter Subject
Cancel
Send
News
340B Program: HRSA Proposes to Modify Administrative Dispute Resolution Process
Chapter
  • Chapter

  • Chapter 1

    Access to the ADR Process
  • Chapter 2

    Rules for Filing Claims
  • Chapter 3

    ADR Panel Composed Entirely of OPA Staff
  • Chapter 4

    Requests for Information
  • Chapter 5

    ADR Decision-Making Process
  • Chapter 6

    Reconsideration Requests

On November 30, 2022, the Health Resources and Services Administration (HRSA) published a proposed rule (Proposed Rule) in the Federal Register that proposes to introduce several changes to the current administrative dispute resolution (ADR) process for the 340B Drug Pricing Program (340B Program). The Proposed Rule comes nearly two years after HRSA finalized the 2020 final rule governing the current ADR process (2020 Final Rule), which is currently the subject of litigation.

As a general matter, and as detailed below, the Proposed Rule would place access to and the results of the ADR process more firmly in the control of the HRSA Office of Pharmacy Affairs (OPA), as compared to the current process. If the Proposed Rule is finalized, any in-process claims submitted pursuant to the 2020 Final Rule will automatically be transferred to the new ADR process. HRSA is accepting comments on the Proposed Rule until January 30, 2023.

Chapter 1

1

Access to the ADR Process

expanded collapse

HRSA’s stated goal in revising the ADR process is to improve its accessibility, administrative feasibility, and timeliness. HRSA purports to accomplish this by making the process less trial-like and more like an administrative process. For example, the Proposed Rule moves away from the use of the Federal Rules of Evidence and Civil Procedure under the existing ADR process, which HRSA believes could create unnecessary delays and prevent potential petitioners from accessing ADR. Overall, HRSA seeks to create a process that all entities can access without regard to their ability to retain counsel or engage in a lengthy trial, which is more likely to have been a barrier to covered entities than to manufacturers.

Chapter 2

2

Rules for Filing Claims

expanded collapse
  • General Rules. Most of the filing rules from the existing ADR process would remain in place under the Proposed Rule. For instance, the Proposed Rule continues to require covered entities and manufacturers to file their written claim within three years of the alleged violation, and to include supporting documentation that supports the basis for the claim.
     
  • Good Faith. Efforts to Resolve Claim. The Proposed Rule newly requires that the party filing the claim submit a written summary of attempts to work in good faith to resolve the claim with the other party. HRSA seeks comments on what evidence would demonstrate good faith and whether it should establish a threshold for attempts at communication.
     
  • Limiting Claims. HRSA states in the Proposed Rule that the ADR process “should be reserved for those disputes set forth in the statutory ADR provision (overcharge, diversion, or duplicate discounts),” and seeks comments on whether there may be appropriate limitations to ensure that ADR is limited to the statutorily specified dispute types.  
     
  • Minimum Threshold. The Proposed Rule seeks to make the process more accessible to small covered entities by eliminating entirely the existing jurisdictional threshold of $25,000. HRSA seeks comment on whether to retain the existing minimum threshold, eliminate the minimum threshold as proposed, or set a new minimum threshold for submitting a claim.
     
  • Initial Review for Completeness. Unlike the current ADR process, where claims are sent directly to the ADR Panel, the Proposed Rule provides that OPA will initially review submitted claims and request additional information as needed. The OPA staff conducting the initial review of a claim will not be appointed to serve on the ADR Panel reviewing that claim. If OPA determines the claim is not complete, the claim will not move forward to the ADR Panel.

If OPA determines the claim is complete, the opposing party will be notified and will have 30 business days to respond or request an extension. Upon receiving the response, OPA will forward the claim and response to the ADR Panel. If the opposing party fails to timely respond, OPA will still forward the claim to the ADR Panel for review.

Chapter 3

3

ADR Panel Composed Entirely of OPA Staff

expanded collapse

The Proposed Rule would change the composition of the ADR Panel by limiting the panel to subject matter experts from OPA. This would alter the current 340B ADR process, which requires the Department of Health and Human Services (HHS) to establish a six-member ADR Board, comprised of equal numbers of individuals from HRSA, the Centers for Medicare & Medicaid Services, and the HHS Office of the General Counsel. The Proposed Rule would instead require the OPA director to choose three individuals, from a “Roster” of 10 pre-selected subject matter experts from OPA, to oversee each ADR claim. Panel members would continue to be screened for conflicts of interest, and the OPA Director and HHS Secretary would have the authority to remove an individual from the panel for reasons including a conflict of interest. HRSA requests comment on the size and composition of the ADR Panel. 

Chapter 4

4

Requests for Information

expanded collapse

Similar to the existing ADR process, the Proposed Rule would permit a covered entity to request “information and documents from the manufacturers and third parties relevant to a claim that a covered entity has been overcharged by the manufacturer.” No similar right is available to manufacturers. In contrast to the existing ADR process, where a covered entity submits a request for information directly to a manufacturer after the ADR Panel deems the request reasonable, the Proposed Rule provides that information requests will be facilitated by the ADR Panel. 

Chapter 5

5

ADR Decision-Making Process

expanded collapse

Once OPA forwards a claim to the ADR Panel, the panel will conduct an initial review to determine if the claim is within its jurisdiction and if the issue involved is being litigated in federal court. In the latter case, the panel will suspend review until the matter is no longer pending in court. If the ADR Panel proceeds with reviewing the claim, it will evaluate all documentation associated with the claim and request additional information as necessary. The panel must base its decision on the documents submitted for review, but may also request additional information from or meet with the parties or others.

As in the existing rule, the panel will set the timeline for reviewing a claim based on the complexity of the claim. When review is complete, the ADR Panel must make a decision supported by a majority of its members, and circulate a decision letter to the parties setting forth its findings and an explanation of the decision.

Chapter 6

6

Reconsideration Requests

expanded collapse

Under the existing ADR process, the decision of the ADR Panel constitutes a final agency decision, and there is no appeals process or other recourse available except through judicial review. By contrast, the Proposed Rule would introduce a new provision that permits either party to initiate a reconsideration request to the HRSA Administrator within 20 business days of the panel's decision letter. The HRSA Administrator could also initiate a reconsideration if neither parties makes a request.

Once the decision becomes final, the OPA Director “will determine any necessary corrective action, or consider whether to take enforcement action, and the form of any such action.”

 

As always, it is important that you carefully review this regulation in light of considerations that may be relevant to your organization. Please feel free to contact the Hogan Lovells Government Price Reporting Team if you have any questions or concerns.

 

 

Authored by Alice Valder Curran, Ken Choe, Kathleen Peterson, Samantha D. Marshall, Ashley Ifeadike, Katherine Kramer, Mahmud Brifkani, and Rianna Modi.

Contacts

bio-image

Alice Valder Curran

Partner

location Washington, D.C.

email Email me

bio-image

Kathleen A. Peterson

Counsel

location Washington, D.C.

email Email me

bio-image

Samantha D. Marshall

Counsel

location Washington, D.C.

email Email me

bio-image

Ashley Ifeadike

Associate

location Washington, D.C.

email Email me

bio-image

Mahmud Brifkani

Senior Associate

location Washington, D.C.

email Email me

bio-image

Katie E. Kramer

Associate

location Washington, D.C.

email Email me

bio-image

Rianna Modi

Associate

location Washington, D.C.

email Email me

View more

More on this topic

image1
Insights and Analysis

Hot on the heels – Hong Kong Court continues to favour corporate restructuring of overseas entities

08 April 2020

image1
News

340B Program: HRSA Issues Administrative Dispute Resolution Final Rule

14 December 2020

View more

left_arrow
right_arrow

Additional Resources

  • Federal Register - 340B Drug Pricing Program; Administrative Dispute Resolution (Proposed Rule)

Related topics

  • Advertising and Promotion of Pharmaceuticals and Biotechnology
  • Biologics and Biosimilars
  • Controlled Substances
  • Life Cycle Management of Pharmaceuticals and Biotechnology
  • Regulatory Exclusivities, Hatch-Waxman, and Similar Statutes
  • Cell, Tissue, and Gene Therapies (CTGT)
  • Life Science Government Enforcement and Compliance
  • Coverage and Reimbursement
  • Drug Pricing and Government Reporting
  • Health Compliance, Fraud and Abuse
  • Health Insurance Plans and Managed Care
  • Health Policy and Advocacy
  • Emerging Companies and Investors
Load more

Related countries

  • United States
Load more

Related keywords

  • final rule
  • hrsa
  • hhs
  • adr
  • administrative dispute resolution
  • 34b
  • drug pricing
  • 216 proposed rule
  • 22 final rule
  • medicaid
  • nprm
  • covered entity
  • adr board
  • adr panel
  • combining claims
  • final agency decision
  • 222 final rule
Load more

Articles you may be interested in

image_1
News

Life Sciences & Health Care Horizons 2025

01 May 2025

image_1
News

Publicly Traded Life Sciences Companies and Artificial Intelligence: Disclosing Risk Factors

30 October 2024

image_1
News

HRSA issues 340B Program final rule modifying administrative dispute resolution process

19 April 2024

image_1
News

2024 Life Sciences & Health Care Horizons

18 April 2024

image_1
News

The Genesis case: The beginning of the end of HRSA’s “patient” definition?

07 November 2023

image_1
News

France to update French National Authority for Health medicinal product doctrine!

20 February 2023

left_arrow
right_arrow

View more insights and analysis

arrow
arrow
"" ""
Digital Client Solutions
Empowering you to lead change through our digital solutions.
Learn more

Register now to receive personalized content and more!

 

Register
close
See benefits
Register
Hogan Lovells logo
Contact us
Quick Links
  • About us
  • Careers
  • Case studies
  • Contact us
  • HL Inclusion
  • Our people
  • Our thinking
  • Responsible Business
  • Cookies
  • Disclaimer
  • Fraudulent and Scam Emails
  • Legal notices
  • Modern Slavery Statement
  • Our thinking terms of use
  • Privacy
  • RSS
Connect with us
LinkedIn
Youtube
Twitter
Wechat
Stay in the know

© 2025 Hogan Lovells. All rights reserved. "Hogan Lovells" or the “firm” refers to the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses, each of which is a separate legal entity. Attorney advertising. Prior results do not guarantee a similar outcome.

Subscribe to Our thinking
Connect with us
LinkedIn
Youtube
Twitter
Wechat